The US Food and Drug Administration (FDA) has approved Novo Nordisk's (NYSE:NVO) Ozempic for treating chronic kidney disease in individuals with type 2 diabetes.
It expands the medication’s use beyond its role in managing blood sugar levels and weight loss.
Specifically, the approval allows Ozempic to be prescribed to slow the progression of kidney disease, reduce the risk of kidney failure, and lower the chances of death due to cardiovascular complications.
Chronic kidney disease, a leading cause of death in the US, results from gradual kidney function decline.
Medical experts believe this expanded use could significantly alter treatment approaches for diabetic patients at risk of kidney failure.
Ozempic, originally developed for diabetes management, has gained popularity for weight loss, leading to high demand. With this new approval, its role in treating chronic conditions is expected to grow.